Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by End-User
3.3. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of PCOS
4.1.1.2. XX
4.1.2. Restraints
4.1.2.1. Lack of Approved Therapeutics
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs
6. By Drug Class
6.1. Introduction
6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Class
6.1.2. Market Attractiveness Index, By Drug Class
6.2. Oral Contraceptives*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Ethinyl Estradiol + Progestins
6.2.4. Levonorgestrel
6.2.5. Drospirenone
6.2.6. Desogestrel
6.2.7. Norgestimate
6.2.8. Cyproterone Acetate
6.2.9. Progestin
6.3. Insulin-Sensitizing Agents
6.3.1. Metformin
6.3.2. Thiazolidinediones (TZDs)
6.4. Antiandrogens
6.4.1. Spironolactone
6.4.2. Finasteride
6.5. Anti-Obesity Drugs
6.5.1. Orlistat
6.5.2. Liraglutide
6.6. Others
6.7. Surgical Procedures
6.7.1. Ovarian Wedge Resection
6.7.2. Laparoscopic Ovarian Drilling
7. By End-User
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
7.1.2. Market Attractiveness Index, By End-User
7.2. Hospitals *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Specialty Clinics
7.4. Others
8. By Region
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.5.1. U.S.
8.2.5.2. Canada
8.2.5.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.5.1. Germany
8.3.5.2. U.K.
8.3.5.3. France
8.3.5.4. Spain
8.3.5.5. Italy
8.3.5.6. Rest of Europe
8.4. South America
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.5.1. Brazil
8.4.5.2. Argentina
8.4.5.3. Rest of South America
8.5. Asia-Pacific
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.5.5.1. China
8.5.5.2. India
8.5.5.3. Japan
8.5.5.4. South Korea
8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
8.6.1. Introduction
8.6.2. Key Region-Specific Dynamics
8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9. Competitive Landscape
9.1. Competitive Scenario
9.2. Market Positioning/Share Analysis
9.3. Mergers and Acquisitions Analysis
10. Company Profiles
10.1. Teva Pharmaceuticals USA, Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.2.3. Historic and Forecasted Product Sales
10.1.2.4. Product Sales Volume
10.1.3. Financial Overview
10.1.3.1. Company Revenue’s
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals etc.
10.1.5. SWOT Analysis
10.2. Bayer AG
10.3. Johnson & Johnson
10.4. Bristol-Myers Squibb Company
10.5. Takeda Pharmaceutical Company Limited
10.6. GSK plc.
10.7. Pfizer Inc.
10.8. CMP Pharma
10.9. Merck & Co., Inc.
10.10. F. Hoffmann-La Roche Ltd
10.11. CHEPLAPHARM Arzneimittel GmbH (H2 Pharma)
LIST NOT EXHAUSTIVE
11. Appendix
11.1. About Us and Services
11.2. Contact Us